According to Surveyed Physicians, Oral Vancomycin and Optimer/Cubist/Astellas’ Dificid are the Top Performing Drugs in the Treatment of CDAD BioTrends Research Group and Arlington Medical Resources Release TreatmentTrends^®:Clostridium difficile Infections (U.S.) Report Business Wire EXTON, Pa. -- December 17, 2012 BioTrends Research Group and AMR in their TreatmentTrends^®: Clostridium difficile Infections (U.S.) report find that metronidazole and oral vancomycin continue to be the workhorse drugs for the treatment of Clostridium difficile-associated diarrhea (CDAD), but metronidazole is likely to lose market share, owing to metronidazole treatment failures. Furthermore, physicians perceive both oral vancomycin and Optimer/Cubist/Astellas’ Dificid (fidaxomicin) as the leading performers in areas that are important to prescribing practices for CDAD, including lower risk for relapse, efficacy in severe CDAD, and efficacy in recurrent infections. Moreover, about half of surveyed physicians indicate that fidaxomicin, Salix’s Xifaxan (rifaximin), and fecal transplants stand to gain from increases in physician use in the next 12 months. Surveyed physicians also note that a notable segment of the CDAD patient population is unable to take oral capsules, and approximately 40 percent of CDAD patients are administered therapies via alternative routes, including IV, enema, and nasogastric tube. Indeed almost all physicians report using IV metronidazole in the past 12 months for CDAD, but, nearly one-third have also used Pfizer’s IV Tygacil (tigecycline) for this indication. “In addition to the overall need for effective therapies with high cure rates, therapies that prevent CDAD recurrences, and for those that have proven efficacy in recurrent infections, effective IV CDAD therapies also have a place in the CDAD market, specifically among patients that cannot tolerate oral therapies,” said Associate Therapeutic Class Director of Infectious Diseases Brenda Perez-Cheeks, Ph.D. “This is an area where tigecycline, which has potent activity against C. difficile and is emerging as a salvage therapy for CDAD, could gain patient share and differentiate itself from the competition” With respect to emerging CDAD therapies, physicians generally have low awareness of agents in development for treatment of CDAD; approximately 10 percent of physicians are aware of Merck’s 3415A and Cubist’s CB-315, while only 4 percent are aware of Actelion’s ACT-179811 (cadazolid). About TreatmentTrends TreatmentTrends: Clostridium difficile Infections (US) is an annual report that analyzes the usage and uptake of therapies and fecal transplantations for the treatment of CDAD. TreatmentTrends is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected and current use of antibiotics in the hospital. About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company. About Arlington Medical Resources AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient and hospital databases that directly link anti-infective drugs with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group atwww.DecisionResourcesGroup.com. All company, brand, or product names contained in this document may be trademarks of their respective holders. Contact: BioTrends Research Group, LLC Brenda Perez-Cheeks, Ph.D., 610-908-7255 firstname.lastname@example.org or Decision Resources Group Christopher Comfort, 781-993-2597 email@example.com
According to Surveyed Physicians, Oral Vancomycin and Optimer/Cubist/Astellas’ Dificid are the Top Performing Drugs in the
Press spacebar to pause and continue. Press esc to stop.